Wolff-Parkinson-White syndrome consensus statement: Difference between revisions
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
==[[Recommendations for Management of Asymptomatic Patients With Asymptomatic pre-excitation]]== | ==[[Recommendations for Management of Asymptomatic Patients With Asymptomatic pre-excitation]]== <ref name="PageJoglar2016">{{cite journal|last1=Page|first1=Richard L.|last2=Joglar|first2=José A.|last3=Caldwell|first3=Mary A.|last4=Calkins|first4=Hugh|last5=Conti|first5=Jamie B.|last6=Deal|first6=Barbara J.|last7=Estes III|first7=N.A. Mark|last8=Field|first8=Michael E.|last9=Goldberger|first9=Zachary D.|last10=Hammill|first10=Stephen C.|last11=Indik|first11=Julia H.|last12=Lindsay|first12=Bruce D.|last13=Olshansky|first13=Brian|last14=Russo|first14=Andrea M.|last15=Shen|first15=Win-Kuang|last16=Tracy|first16=Cynthia M.|last17=Al-Khatib|first17=Sana M.|title=2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia|journal=Heart Rhythm|volume=13|issue=4|year=2016|pages=e136–e221|issn=15475271|doi=10.1016/j.hrthm.2015.09.019}}</ref> | ||
{| class="wikitable" | {| class="wikitable" | ||
|- | |- | ||
Revision as of 05:46, 15 September 2020
|
Wolff-Parkinson-White syndrome Microchapters |
|
Differentiating Wolff-Parkinson-White syndrome from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Wolff-Parkinson-White syndrome consensus statement On the Web |
|
Wolff-Parkinson-White syndrome consensus statement in the news |
|
Risk calculators and risk factors for Wolff-Parkinson-White syndrome consensus statement |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]; Kashish Goel, M.D.
==Recommendations for Management of Asymptomatic Patients With Asymptomatic pre-excitation== [1]
| The class of Recommendation(COR) | Recommendations |
|---|---|
| 1 | In asymptomatic patients with pre-excitation, the findings of abrupt loss of conduction over
manifest pathway during exercise testing in sinus rhythm or intermittent loss of-excitation during ECG or ambulatory monitoring is useful to identify patients at low risk of rapid conduction over the pathway |
| 2a | An EP study is reasonable in asymptomatic patients with pre-excitation to risk-stratify for
arrhythmic events |
| 2a | Catheter ablation of the accessory pathway is reasonable in asymptomatic patients with pre-
excitation if an EP study identifies a high risk of arrhythmic events, including rapidly conducting pre-excited AF |
| 2a | Catheter ablation of the accessory pathway is reasonable in asymptomatic patients if the presence of
pre-excitation precludes specific employment(such as with pilots) |
| 2a | Observation,without further evaluation or treatment,is reasonable in asymptomatic patients
with pre-excitation |
References
- ↑ Page, Richard L.; Joglar, José A.; Caldwell, Mary A.; Calkins, Hugh; Conti, Jamie B.; Deal, Barbara J.; Estes III, N.A. Mark; Field, Michael E.; Goldberger, Zachary D.; Hammill, Stephen C.; Indik, Julia H.; Lindsay, Bruce D.; Olshansky, Brian; Russo, Andrea M.; Shen, Win-Kuang; Tracy, Cynthia M.; Al-Khatib, Sana M. (2016). "2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia". Heart Rhythm. 13 (4): e136–e221. doi:10.1016/j.hrthm.2015.09.019. ISSN 1547-5271.